New biomarkers of Maillard reaction damage to proteins
- PMID: 9044306
- DOI: 10.1093/ndt/11.supp5.41
New biomarkers of Maillard reaction damage to proteins
Abstract
The amount of advanced glycation end-products (AGE) in tissue proteins increases in diabetes mellitus, and the concentration of a subclass of AGEs, known as glycoxidation products, also increases with chronological age in proteins. The rate of accumulation of glycoxidation products is accelerated in diabetes and age-adjusted concentrations of two glycoxidation products, N epsilon-(carboxymethyl)lysine (CML) and pentosidine, correlate with the severity of complication in diabetic patients. Although AGEs and glycoxidation products are implicated in the development of diabetic complications, these compounds are present at only trace concentrations in tissue proteins and account for only a fraction of the chemical modifications in AGE proteins prepared in vitro. The future of the AGE hypothesis depends on the chemical characterization of a significant fraction of the total AGEs in tissue proteins, a quantitative assessment of their effects on protein structure and function, and an assessment of their role as mediators of biological responses. In this manuscript we describe recent work leading to characterization of new AGEs and glycoxidation products. These compounds include: (1) the imidazolone adduct formed by reaction of 3-deoxyglucosone with arginine residues in protein; (2) N epsilon-(carboxyethyl)lysine, an analogue of CML formed on reaction of methylglyoxal with lysine; (3) glyoxal-lysine dimer; and (4) methyl-glyoxal-lysine dimer, which are imidazolium crosslinks formed by reaction of glyoxal or methylglyoxal with lysine residues in protein. The presence of 3-deoxyglucosone, methylglyoxal and glyoxal in vivo and the formation of the above AGEs in model carbonyl-amine reaction systems suggests that these AGEs are also formed in vivo and contribute to tissue damage resulting from the Maillard reaction.
Similar articles
-
Chemical modification of proteins by methylglyoxal.Cell Mol Biol (Noisy-le-grand). 1998 Nov;44(7):1139-45. Cell Mol Biol (Noisy-le-grand). 1998. PMID: 9846896
-
Advanced glycation endproducts in food and their effects on health.Food Chem Toxicol. 2013 Oct;60:10-37. doi: 10.1016/j.fct.2013.06.052. Epub 2013 Jul 16. Food Chem Toxicol. 2013. PMID: 23867544 Review.
-
N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.Biochemistry. 1995 Aug 29;34(34):10872-8. doi: 10.1021/bi00034a021. Biochemistry. 1995. PMID: 7662668
-
Advanced Maillard reaction end products are associated with Alzheimer disease pathology.Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5710-4. doi: 10.1073/pnas.91.12.5710. Proc Natl Acad Sci U S A. 1994. PMID: 8202552 Free PMC article.
-
Structure of advanced Maillard reaction products and their pathological role.Nephrol Dial Transplant. 1996;11 Suppl 5:20-6. doi: 10.1093/ndt/11.supp5.20. Nephrol Dial Transplant. 1996. PMID: 9044302 Review.
Cited by
-
Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Semin Dial. 2012 Sep-Oct;25(5):529-38. doi: 10.1111/j.1525-139X.2012.01081.x. Epub 2012 Apr 30. Semin Dial. 2012. PMID: 22548330 Free PMC article. Review.
-
Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin.Lipids. 2012 May;47(5):443-50. doi: 10.1007/s11745-011-3647-9. Epub 2012 Jan 21. Lipids. 2012. PMID: 22271422
-
Urinary biomarkers of oxidative status.Clin Chim Acta. 2012 Oct 9;413(19-20):1446-53. doi: 10.1016/j.cca.2012.06.012. Epub 2012 Jun 7. Clin Chim Acta. 2012. PMID: 22683781 Free PMC article. Review.
-
Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lenses.Mol Cell Biochem. 2006 Aug;288(1-2):29-36. doi: 10.1007/s11010-005-9115-1. Epub 2006 Apr 1. Mol Cell Biochem. 2006. PMID: 16583141
-
(R)-α-Lipoic acid inhibits fructose-induced myoglobin fructation and the formation of advanced glycation end products (AGEs) in vitro.BMC Complement Altern Med. 2018 Jan 15;18(1):13. doi: 10.1186/s12906-017-2076-6. BMC Complement Altern Med. 2018. PMID: 29334926 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources